Jiahe BioPD-1 monotophoid submitted a new drug listing application for the treatment of peripheral T-cell lymphoma.

On July 21, Jiahe Bio announced that its application for a new drug (NDA) for the PD-1 antibody Geptanolimab (geptanolimab, the development code GB226) had been accepted by the State Drug Administration of China (NMPA) for the treatment of peripheral T-cell lymphoma (PTCL).
Geno monotophosis is a human-derived IgG4 monoclonal antibody that targets immune cell PD-1, and Jiahe bio has core intellectual property rights.
, Genomono can restore the immune system's ability to recognize and kill cancer cells by selectively blocking dual ligands (PD-L1 and PD-L2), and is to be developed to treat a variety of late-stage solid tumors.
currently, Jiahe Bio is conducting a number of clinical trials on Genomono, involving anisotopic T-cell lymphoma, primary large B-cell lymphoma, cervical cancer, non-small cell lung cancer (NSCLC), adenosystsar soft tissue sarcoma and other indications.
include two key Phase 2 clinical studies: one designed to assess the effectiveness and safety of Geno supret sepsis treatment recurrence and incurable exophral T-cell lymphoma, which is also the indication that the Geno supad application is on the market, and the other designed to assess the overall remission rate (ORR) of Geno supma relapse or refractive primary b cell lymphoma.
At this year's American Cancer Research Association (AACR) online meeting, Professor Shi Yuankai, vice president of the Oncology Hospital of the Chinese Academy of Medical Sciences and deputy director of the National Cancer Center, released data on a multi-centered, open, single-arm phase 2 clinical trial for relapsed and incurable peripheral T-cell lymphoma.
the study recruited 102 patients in China, with the main study endpoint being objective mitigation rate, and secondary studies including mitigation duration, disease control rate, progression-free survival, total survival, safety and immunogenicity.
studies have shown significant efficacy in patients with relapsed or refracted peripheral T-cell lymphoma: the Independent Imaging Evaluation Board (IRC) assessed an ORR of 36.3 percent, and the primary subtype of peripheral T-cell lymphoma benefited, with ALK-negative transcell lymphoma ORR of up to 58.3%;
it is worth mentioning that, while studying the efficacy of Geno synofdrine, Jiahe Bio is also actively exploring the combined therapeutic effects of Genosaandand and other drugs: in October 2018, Jiahe Bio and Hutchison Whampoa, a subsidiary of Hehuang Pharmaceuticals, reached a partnership to explore the effects of Genosina and the latter's VEGFR inhibitor furinib in late-stage solid tumors; In December 2018, Jiahe Biology and AXA Pharmaceuticals reached a strategic partnership to explore the combined effects of Genosa and the latter's MDM2-p53 inhibitor APG-115 in the field of solid tumor and malignant blood tumor treatment; Founded in 2007,
Jiahe Bio focuses on the development and commercialization of oncology and autoimmune drugs.
has established a product pipeline of 15 targeted drug candidates, according to Jiahe's bio-website.
note, the company filed a listing application on the Hong Kong Stock Exchange on June 26 after announcing the completion of Jia's $160 million Round B financing on June 1.
References , Jiahe Biopharmaceuticals announced that the application for the listing of the new drug Geptanolimab has been accepted , retrieved Jul 21, 2020 , from Jiaandi Bio at the 2020 AACR Annual Meeting to announce the results of Geptanolimab mono-antitherapy PTCL and ASPS . Retrieved April 29, 2020, from.